Yutao Xiu

Mr. Yutao Xiu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2026 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LXLinyuan Xue
Linyuan Xue
JLJiyixuan Li
Jiyixuan Li
LSLi Sun
Li Sun
TLTing Liu
Ting Liu
BLBen Lam
Ben Lam
DXDongming Xing
Dongming Xing

21 September 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
CWChao Wang
Chao Wang
YXYutao Xiu
Yutao Xiu
YZYujing Zhang
Yujing Zhang
JXJiazhen Xu
Jiazhen Xu
YWYanhong Wang
Yanhong Wang
DXDongming Xing
Dongming Xing
Combination chemotherapy often suffers from asynchronous pharmacokinetics and off-target toxicity. To address this, we designed a novel, unreported engineered prodrug—a redox-responsive bimolecular prodrug (CA-4-Gefitinib)—by engineering a disulfide bond as a cleavable linker to covalently conjugate the tubulin inhibitor combretastatin A-4 (CA-4) and the EGFR inhibitor Gefitinib. This molecular-level prodrug design enables tumor-selective drug activation in high-glutathione environments. This prodrug exhibited enhanced cellular uptake and potent antiproliferative activity against SGC-7901 gastric cancer cells, with significantly improved selectivity over normal cells (safety index of 98). Mechanistically, this engineered prodrug disrupted microtubule polymerization, induced G2/M arrest, suppressed ERK signaling, and promoted apoptosis. The prodrug’s pharmacokinetic profile showed prolonged circulation and reduced systemic exposure to free CA-4, indicating favorable biodistribution. In a murine xenograft model, this prodrug demonstrated superior antitumor efficacy and markedly reduced systemic toxicity compared to the combination of free drugs. Our work presents a rational prodrug design strategy—a redox-responsive drug–drug conjugate prodrug—that synchronizes drug delivery, enhances tumor targeting, and maximizes synergistic efficacy, offering a promising platform for advanced cancer combination therapy.